80 related articles for article (PubMed ID: 7853186)
1. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
Bell RL; Bouska JB; Malo PE; Lanni C; Harris RR; Otis ER; Stewart AO; Brooks DW; Carter GW
J Pharmacol Exp Ther; 1995 Feb; 272(2):724-31. PubMed ID: 7853186
[TBL] [Abstract][Full Text] [Related]
2. 5-lipoxygenase inhibitory activity of zileuton.
Carter GW; Young PR; Albert DH; Bouska J; Dyer R; Bell RL; Summers JB; Brooks DW
J Pharmacol Exp Ther; 1991 Mar; 256(3):929-37. PubMed ID: 1848634
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
[TBL] [Abstract][Full Text] [Related]
4. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
5. Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
Malamas MS; Carlson RP; Grimes D; Howell R; Glaser K; Gunawan I; Nelson JA; Kanzelberger M; Shah U; Hartman DA
J Med Chem; 1996 Jan; 39(1):237-45. PubMed ID: 8568813
[TBL] [Abstract][Full Text] [Related]
6. Effect of 5-lipoxygenase inhibitors on in situ LTB4 biosynthesis following calcium ionophore stimulation in the rat pleural cavity.
Raychaudhuri A; Chertock H; Peppard J; White WD; Koeler J; DiPasquale G
Agents Actions; 1993; 39 Spec No():C43-5. PubMed ID: 8273581
[TBL] [Abstract][Full Text] [Related]
7. A-78773: a selective, potent 5-lipoxygenase inhibitor.
Bell RL; Brooks DW; Young PR; Lanni C; Stewart AO; Bouska J; Malo PE; Carter GW
J Lipid Mediat; 1993; 6(1-3):259-64. PubMed ID: 8395248
[TBL] [Abstract][Full Text] [Related]
8. (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
Brooks CD; Stewart AO; Basha A; Bhatia P; Ratajczyk JD; Martin JG; Craig RA; Kolasa T; Bouska JB; Lanni C
J Med Chem; 1995 Nov; 38(24):4768-75. PubMed ID: 7490726
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of leukotriene B4 biosynthesis by disulfiram and A-64077 during carrageenan-induced pleurisy in the rat.
Riendeau D; Guay J; Foster A; Wolfe S; Chan CC
Gen Pharmacol; 1991; 22(2):371-4. PubMed ID: 1647348
[TBL] [Abstract][Full Text] [Related]
10. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
[TBL] [Abstract][Full Text] [Related]
11. The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor.
Bell RL; Bouska J; Young PR; Lanni C; Machinist J; Malo PE; Summers JB; Brooks DW; Carter GW
Agents Actions; 1993 Mar; 38(3-4):178-87. PubMed ID: 8213344
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton.
Rao NL; Dunford PJ; Xue X; Jiang X; Lundeen KA; Coles F; Riley JP; Williams KN; Grice CA; Edwards JP; Karlsson L; Fourie AM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1154-60. PubMed ID: 17371808
[TBL] [Abstract][Full Text] [Related]
13. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model.
Horizoe T; Nagakura N; Chiba K; Shirota H; Shinoda M; Kobayashi N; Numata H; Okamoto Y; Kobayashi S
Inflamm Res; 1998 Oct; 47(10):375-83. PubMed ID: 9831321
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773.
Carter GW; Bell RL; Marsh K; Lanni C; Awni WM; Bouska J; Stewart AO; Hansen R; Dubé L; Brooks DW
Ann N Y Acad Sci; 1994 Nov; 744():262-73. PubMed ID: 7825849
[TBL] [Abstract][Full Text] [Related]
15. Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
Satoh Y; Powers C; Toledo LM; Kowalski TJ; Peters PA; Kimble EF
J Med Chem; 1995 Jan; 38(1):68-75. PubMed ID: 7837242
[TBL] [Abstract][Full Text] [Related]
16. Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays.
Smith WG; Shaffer AF; Currie JL; Thompson JM; Kim S; Rao T; Isakson PC
J Pharmacol Exp Ther; 1995 Dec; 275(3):1332-8. PubMed ID: 8531100
[TBL] [Abstract][Full Text] [Related]
17. Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part II: Biochemical studies in the human neutrophil.
Jacobson PB; Jacobs RS
J Pharmacol Exp Ther; 1992 Aug; 262(2):874-82. PubMed ID: 1323665
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of fenleuton, a 5-lipoxygenase inhibitor, in ponies.
Marr K; Marsh K; Hernandez L; Cunningham FM; Lees P
Res Vet Sci; 1998; 64(2):111-7. PubMed ID: 9625466
[TBL] [Abstract][Full Text] [Related]
19. Lyprinol inhibits LTB4 production by human monocytes.
Dugas B
Allerg Immunol (Paris); 2000 Sep; 32(7):284-9. PubMed ID: 11094642
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies.
Kachur JF; Askonas LJ; Villani-Price D; Ghoreishi-Haack N; Won-Kim S; Liang CD; Russell MA; Smith WG
J Pharmacol Exp Ther; 2002 Feb; 300(2):583-7. PubMed ID: 11805220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
